CD44v6 expression in intraductal papillary mucinous neoplasms of the pancreas

Pancreas

Volumn 39, Issue 1, 2010, Pages 31-35

  Miyasaka, Yoshihiro ^a   Nagai, Eishi ^a   Ohuchida, Kenoki ^a   Nakata, Kohei ^a   Hayashi, Akifumi ^a   Mizumoto, Kazuhiro ^a   Tsuneyoshi, Masazumi ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CD44v6; Intraductal papillary mucinous neoplasm; Invasion pattern; Pancreas; Subtype

Indexed keywords

HERMES ANTIGEN;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; EPITHELIUM; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LYMPH NODE METASTASIS; MALE; METASTASIS; MORPHOGENESIS; PANCREAS ADENOMA; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

ADENOCARCINOMA, MUCINOUS; AGED; ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS;

EID: 74049098590     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181c31049     Document Type: Article

References (40)

1. Longnecker DS, Hruban RH, Adler G, et al. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. Lyon, France: IARC Press; 2000:237-240.
2. Nagai E, Ueki T, Chijiiwa K, et al. Intraductal papillary mucinous neoplasms of the pancreas associated with so-called Bmucinous ductal ectasia.[ Histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 1995;19:576-589.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788-797; discussion 97-99.
4. Adsay NV, Pierson C, Sarkar F, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001;25:26-42.
5. Biankin AV, Biankin SA, Kench JG, et al. Aberrant p16 (INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50:861-868.
6. Miyasaka Y, Nagai E, Yamaguchi H, et al. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2007;13:4371-4377.
7. Chetty R, Serra S, Salahshor S, et al. Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. Hum Pathol. 2006; 37:212-217.
8. Yamaguchi H, Inoue T, Eguchi T, et al. Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol. 2007;20:552-561.
9. Sato N, Fukushima N, Maitra A, et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol. 2004;164:903-914.
10. Yonezawa S, Nakamura A, Horinouchi M, et al. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002;9: 328-341.
11. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an Bintestinal[ pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839-848.
12. Furukawa T, Kloppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794-799.
13. Stamenkovic I, Amiot M, Pesando JM, et al. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell. 1989;56:1057-1062.
14. Goldstein LA, Zhou DF, Picker LJ, et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell. 1989;56:1063-1072.
15. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol. 1989;109:927-937.
16. Shimizu Y, Van Seventer GA, Siraganian R, et al. Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol. 1989; 143:2457-2463.
17. Foger N, Marhaba R, Zoller M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci. 2001; 114:1169-1178.
18. Thomas L, Byers HR, Vink J, et al. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 1992; 118:971-977.
19. Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem. 1992;267: 4732-4739.
20. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991; 65:13-24.
21. Heider KH, Dammrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res. 1993;53: 4197-4203.
22. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754-4756.
23. Yanagisawa N, Mikami T, Mitomi H, et al. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer. 2001;91:408-416.
24. Hoshimoto K, Yamauchi N, Takazawa Y, et al. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract. 2003;199:71-77.
25. Saegusa M, Machida D, Hashimura M, et al. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. J Pathol. 1999;189:326-337.
26. Maruta J, Hashimoto H, Yamashita H, et al. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004;31: 392-396.
27. Gotoda T, Matsumura Y, Kondo H, et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res. 1998;89:1033-1040.
28. Castella EM, Ariza A, Ojanguren I, et al. Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study. Virchows Arch. 1996;429:191-195.
29. Satoh K, Shimosegawa T, Koizumi M, et al. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas. Anticancer Res. 1997;17:215-219.
30. Gansauge F, Gansauge S, Zobywalski A, et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res. 1995;55:5499-5503.
31. Tsukuda H, Matsumura Y, Inoue T, et al. Diagnostic application of CD44 variant expression in pancreatic juice for detection of pancreatic neoplasm. Anticancer Res. 2001;21:2175-2183.
32. Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003;90:1244-1249.
33. Herrera-Gayol A, Jothy S. CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness. Exp Mol Pathol. 1999;66:99-108.
34. Kobel M, Weichert W, Cruwell K, et al. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch. 2004;445:456-464.
35. Sonobe S, Miyamoto H, Nobukawa B, et al. Prognostic value of CD44 isoform expression in thymic epithelial neoplasms. Cancer. 2005;103:2015-2022.
36. Cheng C, Yaffe MB, Sharp PA. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev. 2006;20: 1715-1720.
37. Wada K, Takada T, Yasuda H, et al. Does Bclonal progression[ relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg. 2004;8:289-296.
38. Schonleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007;249:242-248.
39. Dammrich J, Vollmers HP, Heider KH, et al. Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. J Mol Med. 1995;73: 395-401.
40. Heider KH, Kuthan H, Stehle G, et al. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004; 53:567-579.